MAPS submits 2025 cannabis safety update report to the FDA for the MJP2 Phase 2 study

MAPS submits a 2025 cannabis data safety update report to the FDA for the MJP2 Phase 2 study. The filing is framed as a regulatory safety reporting step tied to the ongoing clinical work, using 2025 study information to update the agency on participant safety. The submission matters because it supports FDA oversight and continued progress of the Phase 2 trial for cannabis-based medical research under a structured investigational plan.